EnteroBiotix is a clinical-stage biopharmaceutical company focused on full-spectrum microbiome therapeutics. Its lead product, EBX-102-02, is a next-generation full-spectrum microbiome therapeutic manufactured with proprietary processing technologies intended to enable safe, stable, orally delivered microbial ecosystem restoration. The company positions EBX-102-02 as a potential first disease-modifying therapy for IBS-C and advanced the candidate into a Phase 2b program following positive Phase 2a TrIuMPH trial results in 122 patients. The RISE Phase 2b trial is randomized, double-blind, placebo-controlled and plans to enroll around 300 patients in the UK, with first dosing expected in Q2 2026 and topline data due in H2 2027. EnteroBiotix is building a broader pipeline in high-value gastrointestinal indications associated with significant unmet need. EBX-102-02 is not approved for clinical therapeutic use outside of clinical trials or regulated programmes.

Total raised

$84M

Funding rounds

5

Latest round

Equity

Latest activity

May 2026